阿里拉姆製藥 ALNY 深 滬
等待開盤 03-26 09:30:00 美东时间
328.70
+20.650
+6.70%
華盛通- 最 高329.48
- 今 開313.34
- 成交量 113.96万股
- 最 低 311.71
- 昨 收 308.05
- 總市值 437.17亿
- 52周最高 495.55
- 市盈率 靜 141.10
- 換手率 0.86%
- 52周最低 205.87
- 委 比 -94.48%
- 總股本 1.33亿
- 歷史最高 495.55
- 量 比 0.85
- 振 幅 5.77%
- 歷史最低 5.879
- 每 手 1
- 風險率 75.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alnylam Pharmaceuticals Advancing Approach To Resolve Challenges Of Underdiagnosis And Fragmented Care In ATTR‑CM
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination for patients with
03-24 19:39
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma reported strong financial results for 2025, with $91.5M in cash and marketable securities. The company achieved a significant milestone with a $950M settlement from Moderna for LNP technology infringement. Additionally, two more patients in the Phase 2a trials of imdusiran achieved functional cure for chronic hepatitis B. The company also received a milestone payment for its HCC treatment candidate. Financial performance showed ...
03-23 11:30
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
Royalty Pharma appoints Lucas Glass as Head of Artificial Intelligence, effective April 2026. With over a decade of experience in AI and data solutions, Glass will lead the implementation of cutting-edge AI capabilities, enhancing the company's decision-making and operational efficiency. His appointment underscores Royalty Pharma's commitment to leveraging advanced technologies to strengthen its competitive edge in the biopharmaceutical sector.
03-23 11:15
Royalty Pharma Announces Expansion of Leadership Team
Royalty Pharma appoints Greg Butz as Executive Vice President, Partnering & Investments, effective June 2026. Butz joins from Bank of America, where he was Global Co-Head of Healthcare Investment Banking. The company also promotes Chris Hite to Chairman, Partnering & Investments. Royalty Pharma specializes in acquiring and funding biopharmaceutical royalties, with a portfolio of over 35 commercial products and 19 development-stage candidates.
03-17 20:01
The $3B Biotech With Two Shots On Goal
A cleaner drug, zero competition, and two binary readouts this year. Plus, Powell and oil near $99.
03-17 19:07
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Jefferies Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $330
Jefferies analyst Faisal Khurshid downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Hold and lowers the price target from $522 to $330.
03-16 20:55
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monda
03-16 18:00
百元油价惹急特朗普！今晚PCE通胀数据又将带来“坏消息”？2026年降息一次都悬了
百元油价惹急特朗普！今晚PCE通胀数据又将带来“坏消息”？市场定价2026年一次降息都没有，“鹰派”环境影响美股哪些板块和公司？一文读懂>>
03-13 16:09
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory filings and potential commercial launches.
03-11 02:49
